<qa>  How many groups of patients with MM use the extended 2nd line indication?In this open-label randomised phase I trial, bortezomib will be administrated to 2 groups of 10 patients with MM who have inclusion criteria use the extended 2nd line indication, either intravenously group 1 10 patients or subcutaneously group 2 10 patients. The schedule of administration of bortezomib will be the following : 1.3 mg per square meter of body-surface area twice weekly for 2 weeks, followed by 1 week without treatment, for up to eight cycles, either IV group 1 or SC group 2. 